Loading clinical trials...
Loading clinical trials...
A 8-WEEK, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP, PHASE III STUDY COMPARING THE EFFICACY AND SAFETY OF XALACOM AND XALATAN IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA (POAG) OR OCULAR HYPERTENSION (OH)
This study will examine the efficacy and safety of Xalacom comparing with those of Xalatan in Japanese patients with POAG or OH, in order to show superiority of Xalacom over Xalatan in efficacy and similarity of safety between Xalacom and Xalatan.
Age
20 - No limit years
Sex
ALL
Healthy Volunteers
No
Nomura Eye Clinic
Ichinomiya, Aichi-ken, Japan
Matsusura Eye Clinic
Ichinomiya, Aichi-ken, Japan
Yasuma Eye Clinic
Nagoya, Aichi-ken, Japan
TANABE Eye Clinic
Nagoya, Aichi-ken, Japan
Suzuki Eye Clinic
Nagoya, Aichi-ken, Japan
Mitsuhashi Eye Clinic
Narashino, Chiba, Japan
Ohtsuka Eye Clinic
Sapporo, Hokkaido, Japan
Sasamoto Eye Clinic
Sapporo, Hokkaido, Japan
Ohyachi Kyouritsu Eye Clinic
Sapporo, Hokkaido, Japan
Kaimeido Eye Clinic
Sapporo, Hokkaido, Japan
Start Date
November 14, 2006
Primary Completion Date
October 1, 2007
Completion Date
October 1, 2007
Last Updated
September 8, 2021
300
ACTUAL participants
Xalatan
DRUG
Xalacom
DRUG
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07396441